Key result
Pharmacological therapies for atrial fibrillation remain challenging due to failure to terminate the arrhythmia and prevent recurrence, necessitating the development of novel and emerging agents.
This review summarizes current and emerging pharmacological therapies for the management of atrial fibrillation.
Persistent AF pharmacotherapy limitations warrant caution with current agents; leaves open the efficacy of novel options.
Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia that leads to hospitalizations for complications and adverse events each year. Despite significant improvement in our therapeutic approaches in the past decade, management of AF remains a difficult task. Novel therapies have failed to terminate AF and prevent its recurrence, and patients with AF continue to have thromboembolic complications. With the increasingly aging population and associated conditions, the prevalence of AF is expected to progressively increase, becoming a public health problem. Most patients with AF have multiple comorbidities and are of advanced age, making long-term anticoagulation challenging. This article provides an overview of the current pharmacological therapies for the management of AF, with particular emphasis on the emerging agents.
No takes yet. Share an insight, caveat, or question.
Gooden et al. (2013) conducted a review in Atrial fibrillation. Pharmacological therapies was evaluated. Pharmacological therapies for atrial fibrillation remain challenging due to failure to terminate the arrhythmia and prevent recurrence, necessitating the development of novel and emerging agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: